eFFECTOR Therapeutics Inc
NASDAQ:EFTR
eFFECTOR Therapeutics Inc
NASDAQ:EFTR
Price:
2.2 USD
-2.22%
Updated:
May 2, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of EFTR.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EFTR
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
EFTR Competitors Multiples
eFFECTOR Therapeutics Inc Competitors
eFFECTOR Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
eFFECTOR Therapeutics Inc
NASDAQ:EFTR
|
8.1m USD | 0 | -0.2 | 0.3 | 0.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.5B USD | 5.3 | 22.1 | 16.4 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.8B USD | 7.5 | 25 | 16.6 | 18.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 168.6 | 6.8 | 8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.5 | -8.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.5B USD | 3.3 | 27 | 13.8 | 17.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.3T KRW | 17.9 | 73.4 | 44.9 | 61.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
